BiotechTube

PPAR alpha + placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemia

Conditions

Dyslipidemia

Trial Timeline

Jul 1, 2005 → Oct 1, 2006

NCT ID
NCT00116519

About PPAR alpha + placebo

PPAR alpha + placebo is a phase 2 stage product being developed by Eli Lilly for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00116519. Target conditions include Dyslipidemia.

What happened to similar drugs?

15 of 20 similar drugs in Dyslipidemia were approved

Approved (15) Terminated (3) Active (3)
✅Pitavastatin + PravastatinEli LillyApproved
✅Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
✅rosuvastatin + placebo + rosuvastatin + atorvastatinAstraZenecaApproved
✅FluvastatinNovartisApproved
✅Fluvastatin extended release, fenofibrate + Fixed combination simvastatin/ezetimibeNovartisApproved
✅FluvastatinNovartisApproved
✅Atorvastatin + AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00116519Phase 2Completed

Competing Products

20 competing products in Dyslipidemia

See all competitors
ProductCompanyStageHype Score
LY3202328 + Placebo + Atorvastatin + SimvastatinEli LillyPhase 1
29
Pitavastatin + PravastatinEli LillyApproved
43
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
43
YH14755 + Metformin + RosuvastatinYuhanPhase 3
40
YHR1705 + YHR1706 + YHR1705+YHR1706YuhanPhase 1
29
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
33
Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDCYuhanPhase 1
29
MevalotinDaiichi SankyoPre-clinical
26
PravastatinDaiichi SankyoPre-clinical
26
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SCEli LillyPhase 1
29
LY3885125 + PlaceboEli LillyPhase 1
21
LY3561774 + PlaceboEli LillyPhase 1
29
LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for StatinsEli LillyPhase 2
35
LY3561774 + PlaceboEli LillyPhase 2
35
LY2484595 + Placebo + AtorvastatinEli LillyPhase 2
35
EvacetrapibEli LillyPhase 1
29
AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + PlaceboAstraZenecaPhase 1
29
ABT-335 + RosuvastatinAstraZenecaPhase 1
29
AZD6615 + PlaceboAstraZenecaPhase 1
21
AZD0780 + AZD0780 + AZD0780 + Placebo + Placebo + Placebo + RosuvastatinAstraZenecaPhase 1
29